CanSino Biologics Inc. has released its interim report for the first half of 2026, revealing total revenue of RMB 550 million, a 43.81% increase year-on-year, alongside a significant narrowing of its net loss attributable to shareholders. The most striking performance came from its international operations, which generated RMB 152 million in overseas revenue, marking an extraordinary 4,724.19% surge compared to the same period last year.
Industry observers note this is not merely a case of selling more vaccine doses abroad. CANSINOBIO is accomplishing something few domestic vaccine manufacturers have achieved: rather than simply exporting finished products, the company is systematically transferring its production processes, quality control standards, and industrialization capabilities to overseas markets. This raises a key question: what is driving this remarkable year-on-year growth in international revenue?
The first avenue involves direct exports of established products. The company's quadrivalent meningococcal conjugate vaccine, Menhycia (MCV4), has served as the pioneering product, securing drug registration certificates in Indonesia and Argentina, with commercial supply already underway in Indonesia. Domestically, the vaccine's age indication expansion to cover children from 3 months to 6 years has received approval, while a supplementary application to extend it to age 17 is under review by China's NMPA. Having validated its commercialization and refined its production processes in the domestic market, the company is now replicating this proven approach in emerging markets—a classic and solid foundation for global expansion.
The second avenue, which serves as the core driver of this revenue surge, is the export of technology and industrialization expertise. During the reporting period, CANSINOBIO supplied PCV13i vaccine intermediates to its Indonesian partner, supporting the partner's subsequent industrialization and commercialization efforts, which contributed significantly to the rapid growth in overseas revenue. Leveraging the PIC/S GMP certification obtained for its Malaysian production facility, the company is exporting validated production processes and quality control systems rather than only finished products. Additionally, revenue from vaccine technology transfer services and pharmaceutical process research and development during the period indicates that CANSINOBIO is converting its accumulated industrial know-how into direct income.
Historically, many domestic biopharmaceutical companies have relied on finished product exports for their international expansion, which carries clear limitations—constrained by overseas registration timelines, local distribution capabilities, and transportation costs, making it difficult to scale volumes. CANSINOBIO has developed a composite model that runs four parallel tracks: finished vaccine sales, vaccine intermediate supply, process technology transfer, and overseas collaborative clinical development. The company is advancing multi-product registrations across Southeast Asia, South America, and the Middle East while establishing localized industrial partnerships. In July 2026, the company also signed a cooperation agreement with a Pakistani partner regarding PCV13i.
The value of this approach lies in its independence from single-product sales volumes. Instead, the company transforms over a decade of accumulated industrialization expertise into reusable, exportable assets—a validated production process and quality control framework that can simultaneously engage multiple countries and partners. In the domestic market, CANSINOBIO has completed commercial validation of several innovative vaccines in recent years, including Menhycia, UPeixin, PanKexin (DT3cP, approved in April 2026 with initial batch releases in August), and Taitexin (adsorbed tetanus vaccine, approved in August 2026). Each product's journey from clinical trials to market launch has refined the company's comprehensive capabilities in manufacturing, quality control, and clinical development, which collectively form the solid foundation for its global strategy.
Conversely, overseas revenue helps distribute R&D and production line investments, feeding back into domestic product iteration, while genuine public health needs in foreign markets influence the direction of early-stage pipeline research. Behind this systematic international expansion lie five core technology platforms: viral vector vaccines, synthetic vaccines, protein structure design with VLP assembly, mRNA vaccines, and formulation and delivery technologies. These platforms serve both as the source of new domestic products and as the core of the technology being exported internationally.
While acknowledging these achievements, several practical challenges cannot be overlooked. First, the high growth rate in overseas revenue is measured against an extremely low base from the previous year, and sustainability will depend on the pace of additional product registrations abroad and the actual implementation of local partnerships. Second, the company's operating cash flow remains under pressure. Third, overseas operations carry inherent uncertainties—registration timelines in various countries, local policy environments, geopolitical factors, and partner execution efficiency, any of which could disrupt progress.
The significance of this interim report extends far beyond adding another revenue stream. It represents Chinese innovative vaccine companies exploring a new paradigm for globalization—a qualitative leap from exporting products to exporting an entire system. This marks a fundamental transformation in how China's biopharmaceutical industry approaches international markets.
Comments